 Biological Availability
"Biological Availability" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.
| Descriptor ID |
D001682
|
| MeSH Number(s) |
G03.787.151 G07.690.725.129
|
| Concept/Terms |
Biological Availability- Biological Availability
- Availability, Biological
- Availabilities, Biological
- Biological Availabilities
- Biologic Availability
- Physiologic Availability
- Availability, Biologic
- Availabilities, Biologic
- Biologic Availabilities
- Bioavailability
- Bioavailabilities
- Availability, Physiologic
- Availabilities, Physiologic
- Physiologic Availabilities
Availability Equivalency- Availability Equivalency
- Availability Equivalencies
- Equivalencies, Availability
- Equivalency, Availability
|
Below are MeSH descriptors whose meaning is more general than "Biological Availability".
Below are MeSH descriptors whose meaning is more specific than "Biological Availability".
This graph shows the total number of publications written about "Biological Availability" by people in this website by year, and whether "Biological Availability" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 0 | 1 | 1 | | 1990 | 0 | 2 | 2 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 2 | 2 | | 1998 | 0 | 5 | 5 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 6 | 6 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 8 | 8 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 3 | 3 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 4 | 4 | | 2011 | 0 | 5 | 5 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 5 | 5 | | 2014 | 0 | 5 | 5 | | 2015 | 0 | 3 | 3 | | 2016 | 0 | 3 | 3 | | 2017 | 0 | 3 | 3 | | 2018 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 | | 2021 | 1 | 1 | 2 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Biological Availability" by people in Profiles.
-
Wang K, Hao Y, Wang C, Zhao X, He X, Sun CC. Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization. Int J Pharm. 2022 Mar 25; 616:121541.
-
Song S, Wang C, Wang S, Siegel RA, Sun CC. Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion. Int J Pharm. 2021 Dec 15; 610:121216.
-
Wang L, Liu S, Chen JM, Wang YX, Sun CC. Novel Salt-Cocrystals of Berberine Hydrochloride with Aliphatic Dicarboxylic Acids: Odd-Even Alternation in Physicochemical Properties. Mol Pharm. 2021 04 05; 18(4):1758-1767.
-
Zhou H, Lei M, Wang W, Guo M, Wang J, Zhang H, Qiao L, Feng H, Liu Z, Chen L, Hou J, Wang X, Gu C, Zhao B, Izumchenko E, Yang Y, Zhu Y. In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma. Aging (Albany NY). 2020 11 16; 12(22):22949-22974.
-
Zhao X, Li Q, Wang C, Hu S, He X, Sun CC. Simultaneous taste-masking and oral bioavailability enhancement of Ligustrazine by forming sweet salts. Int J Pharm. 2020 Mar 15; 577:119089.
-
Yang Y, Wysocki E, Antwi K, Niederkofler E, Leung EKY, Lazar-Molnar E, Yeo KJ. Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clin Chim Acta. 2018 Aug; 483:308-314.
-
Offman E, Davidson M, Abu-Rashid M, Chai P, Nilsson C. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2017 Oct; 42(5):815-825.
-
Parsad S, Ratain MJ. Food Effect Studies for Oncology Drug Products. Clin Pharmacol Ther. 2017 May; 101(5):606-612.
-
Knoebel RW, Larson RA. Pepsi® or Coke®? Influence of acid on dasatinib absorption. J Oncol Pharm Pract. 2018 Mar; 24(2):156-158.
-
Benes LB, Bassi NS, Davidson MH. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016; 12:481-490.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|